YpsoMate 2.25 Now Offers an 8 mm Needle Configuration for Improved Patient Comfort.
At Ypsomed, we are committed to continuous innovation and improving patient experiences. Our YpsoMate platform has long been a trusted choice in the pharmaceutical industry, with a proven track record of effectively and reliably delivering various drug formulations. Today, we are excited to announce an additional configuration for our YpsoMate 2.25 autoinjector – it can now be configured for the use with prefilled syringes with an 8 mm needle.
Introducing new options for YpsoMate 2.25
The YpsoMate 2.25 has always stood out for its ergonomic design, ease of use, and patient-centric features. By adding the option to use a PFS with an 8 mm needle , we are enhancing its versatility as well as the patient injection experience. This new configuration is ideal for a wide range of viscosities, making it suitable for various drug formulations and patient needs.
Used needles: 1/2" 27 G/STW and 8 mm 27 G/UTW. For further details on the difference between the inner walls, please read here. Liquid viscosities: 15 cP.
Why an 8 mm needle?
An 8 mm needle offers several advantages, both for patients and medical devices. The combination of a shorter needle with a thinner wall significantly reduces the force required to inject the drug. This substantial improvement makes the injection process with the YpsoMate 2.25 autoinjector quicker and allows for the injection of higher viscosities within the same time frame.
This improvement moreover offers benefits for users, whether utilizing the syringe independently or in conjunction with the autoinjector. The flexibility to choose between the 8 mm needle and the standard ½” needle offers pharmaceutical companies greater customization options tailored to specific drug and patient needs.
Here are the main benefits of the 8 mm needle configuration1:
- Reduced injection force and time: the 8 mm needle reduces the ejection force and injection time required, making the injection process quicker and easier for patients.
- Improved patient preference: studies have shown that 64% of self-injecting chronic disease patients prefer the shorter 8 mm needle due to reduced injection force and enhanced comfort.
- Lower risk of intramuscular injection: the shorter needle length significantly decreases the risk of intramuscular injection, enhancing the safety and effectiveness of the subcutaneous delivery.
- Reduced needle-related anxiety: the 8 mm needle can help reduce needle-related anxiety, making the injection experience less daunting for patients.
Expanding supported viscosities and availability across YpsoMate platform products
The YpsoMate 2.25 with an 8 mm needle can handle viscosity ranges of 1 – 40 cP, while the YpsoMate 2.25 Pro with an 8 mm needle2 accommodates viscosities from 1 – 80 cP, making it suitable for a wide range of drug formulations.
Looking ahead, we are also working on expanding the 8 mm needle configuration option across different members of our YpsoMate platform. This upcoming enhancement ensures that pharmaceutical companies can continue to rely on the trusted performance of our devices while benefiting from added flexibility to meet diverse patient and drug delivery needs. With the integration of the 8 mm needle into more of our products, we aim to deliver the same high standards with even greater adaptability.
Retaining the best features of YpsoMate 2.25
Despite this new configuration, the YpsoMate 2.25 retains all the features that have made it stand-out in the market:
- Push-on-skin activation: this simple mechanism makes the injection process straightforward and ergonomic.
- Audible and visual confirmation: clear “clicks” and a large viewing window enhance patient confidence and control.
- Safety features: the needle remains hidden at all times to prevent accidental needle stick injuries, and the robust design includes a roll-stop feature.
- Customisation: the YpsoMate 2.25 can be tailored to meet unique dosing and design requirements, ensuring it aligns perfectly with your brand and patient needs.
Seamless integration with SmartPilot
The YpsoMate 2.25’s compatibility with the SmartPilot add-on transforms it into a fully connected device, offering advanced adherence monitoring and user guidance. This integration tracks injection events and outcomes, providing valuable data to enhance patient safety and improve treatment outcomes.
Learn more
To discover how the YpsoMate 2.25 with 8 mm needle can meet your drug delivery needs, get in touch with us today. Our team is ready to assist you in customising the perfect solution for your specific requirements.
1 Extracted from: https://www.bd.com/en-us/products-and-solutions/products/product-families/neopak-xtraflow-glass-prefillable-syringe
2 Timeline for readiness of the YpsoMate 2.25 Pro with 8 mm needle not defined yet
Authors
Thomas Fontanellaz
Thomas Fontanellaz is the Category Lead of the YpsoMate 2.25 at Ypsomed Delivery Systems. He leads a group that drives customer customisation projects as well as the lifecycle management of the YpsoMate 2.25 franchise. Mr Fontanellaz has been with Ypsomed since 2017 in a number of roles in development, and marketing and sales, working with pharma and small biotech companies to develop and bring innovative self-injection systems to market. He is a trained electrician and studied mechanical engineering and business administration in Switzerland.
Stay tuned, stay informed
Subscribe to the Ypsomed Blog and join our journey to simpler and easier selfcare.
